The Chinese 2021 guideline for the diagnosis and management of type I diabetes suggests that SGLT2 inhibitors may be considered in T1DM with informed consent and a BMI ≥25 kg/m2 with poor insulin control (5). The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.